Three strategic markets.
One global presence.
MENA · North America · Europe
MENA
141 Md $
Projected MEA Health Market (2025)
IQVIA · OMS · CNUCED
+10%
Annual CAGR
600M+
Target Population
70%
Imported Medicines
MENA: 70% of medicines imported, 10% annual growth.
NORTH AMERICA
635 Md $
North American Pharma Market (2025)
Toward Healthcare, 2025 · EFPIA, 2025
+5,67%
Annual CAGR
385M+
Target Population
42%
Imported Medicines
North America: 42% of the global market, center of pharma innovation.
EUROPE
468 Md $
European Pharma Market (2024)
Toward Healthcare, 2026 · EFPIA, 2025
+5,78%
Annual CAGR
750M+
Target Population
30%
Imported Medicines
Europe: 30% of the global market, projected at $820B by 2034.
Two Directions.
One Trusted Partner.
Pharma & Biotech SMEs — North America & Europe
Turnkey MENA strategy: regulatory compliance, qualified partner identification, time to market accelerated.​
MENA Pharmaceutical Players
Access to North American and European biotech innovation: licensing, co-development, and international distribution.
Why Nexus Pharmalink?
A dedicated expert, not an intermediary
You work directly with Sara Abbad 10+ years of international pharma experience, MENA network activated from day one.
600+ hours
per mandate
Major consulting firm engagement, at conditions accessible to SMEs.​​
​​
​
Compensation
tied to results
80–90% of our compensation
is tied to the success of your transaction.​​
The Nexus Edge, in Numbers
+25%
Revenue Growth
Avg. for clients · First 2 years
-30%
Time to Market
Streamlined regulatory process
+20%
Market Share Gain
Avg. within 2 years of launch